<DOC>
	<DOCNO>NCT02630420</DOCNO>
	<brief_summary>Two-part phase 1B clinical trial combine cextuximab savolitinib treat Ras wild-type colorectal cancer ( CRC ) . Part 1 ass safety tolerability drug combination include patient squamous cell carcinoma head neck cancer , well patient CRC . Part 2 study , focus registration , obtain safety data combination cextuximab savolitinib look efficacy cextuximab savolitinib Ras wild-type mCRC previously treat relapsed cetuximab panitumumab.Correlative study examine tumor blood specimen mechanisms anti-EGFR resistance response MET inhibition .</brief_summary>
	<brief_title>Cetuximab Savolitinib Treatment Ras Wild-Type Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria , Part 1 : 1 . Progressive metastatic unresectable CRC SCCHN . 2 . Prior therapy cetuximab panitumumab . Cetuximab panitumumab could use either alone combination agent . 3 . If patient treat cetuximab past , must able tolerate full dos cetuximab without dose modification toxicity . 4 . ECOG performance status 02 . 5 . Life expectancy least 3 month . 6 . Patient adequate organ function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ≥ 9 g/dL Platelets ( PLT ) ≥ 100 x 109/L AST/ALT ≤ 2.5 x ULN ( ≤ 5 x ULN case liver metastasis ) GGT &lt; 3 x ULN ( &lt; 5 x ULN case liver involvement ) Bilirubin ≤ 1.5 x ULN Albumin ≥ 3 g/dL Serum creatinine ≤ 1.5 x institutional ULN ( Cockcroft Gault formula ) 7 . Adequate contraception applicable . 8 . Ability take oral medication opinion investigator . 9 . Patient able willing comply study procedure per protocol , include biopsy time study enrollment . 10 . Patient able understand willing sign date write voluntary informed consent form ( ICF ) screen visit prior protocolspecific procedure . Inclusion Criteria , Part 2 : 1 . Histologically confirm stage IV colon cancer ( AJCC 7th edition ) progress least one line standard therapy . 2 . Presence measurable disease per RECIST criterion image study time trial enrollment . 3 . Prior therapy cetuximab panitumumab contain regimen disease progression within 3 month last dose cetuximab panitumumab . AntiEGFR antibody could use either alone combination agent . 4 . Subjects disease direct treatment least 4 week prior treatment initiation study . 5 . Absence KRas NRas mutation use extended Ras profiling . 6 . ECOG performance status 02 . 7 . Life expectancy least 3 month . 8 . Patient able receive adequate oral nutrition ≥ 1500 calorie per day free significant nausea vomit 9 . Patient adequate organ function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ≥ 9 g/dL Platelets ( PTL ) ≥ 100 x 109/L AST/ALT ≤ 2.5 x ULN ( ≤ 5 x ULN case liver metastasis ) Bilirubin ≤ 1.5 x ULN Albumin ≥ 3 g/dL Serum creatinine ≤ 1.5 x institutional ULN ( Cockcroft Gault formula ) 10 . Adequate contraception applicable . 11 . Ability take oral medication opinion investigator . 12 . Patient able willing comply study procedure per protocol , include tumor biopsy within 28 day treatment initiation . 13 . Patient able understand willing sign date write voluntary informed consent form screen visit prior protocolspecific procedure . Exclusion Criteria ( Parts 1 2 ) : 1 . Previous treatment MET inhibitor antiMET antibody ( e.g . foretinib , crizotinib , cabozantinib , onartuzumab ) . 2 . Patients previous hypersensitivity cetuximab ( Grade 2 high , unless control &lt; Grade 2 prophylactic measure subsequent exposure ) . 3 . Active dermatological condition require treatment associate grade 2 high skin toxicity . Dermatological condition control treatment maximum grade 1 skin toxicity allow study enrollment . 4 . Symptomatic brain metastasis require treatment . 5 . Other active malignancy within last 3 year ( except nonmelanoma skin cancer noninvasive/in situ cancer ) . 6 . Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication . 7 . Persistent toxicity CTCAE grade 2 high , exception alopecia , cause previous cancer therapy . 8 . Pregnancy breast feed . 9 . Current therapy investigational agent participation another clinical study . 10 . History allergic reaction attribute compound similar chemical biologic composition savolitinib . 11 . Major surgery within 28 day minor surgery within 14 day start study treatment , except tumor biopsy . 12 . Radiotherapy le two week prior start study treatment 13 . Significant current recent ( &lt; 14 day ) gastrointestinal disorder diarrhea major symptom , e.g . Crohn 's disease , malabsorption , CTCAE grade &gt; 2 diarrhea etiology . 14 . Psychological , familial , sociological condition potentially hamper compliance study protocol followup schedule . 15 . Involvement plan and/or conduct study . 16 . Previous enrolment present study . 17 . Acute chronic liver pancreatic disease . 18 . Use strong inducer inhibitor CYP3A4 strong inhibitor CYP1A2 within 2 week first dose study treatment ( 3 week St John 's Wort ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>